Many
studies have demonstrated the clinical benefits of
combining a LABA and an ICS both in asthma and COPD and this has led to
the development of fixed combination inhalers containing a LABA and an ICS in
the same device (LABACS).7
The increased efficacy of the combined administration
of a LABA and an ICS is the final clinical effect of the mutual interaction
that the two classes have at pathophysiological (particularly in asthma) and molecular
levels (asthma and COPD).
|
